Reading IBO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track IBO free→Reading IBO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track IBO free→QuarterlyIQ Insights · IBO
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Entry into a Material Definitive Agreement Amendment to Merger and Share Exchange Agreement As previously disclosed, Impact BioMedical Inc., a Nevada corporation (the “Company” or “Impact”), is party to that certain Merger and Share Exchange Agreement, dated June 21, 2025 (the “Original Merger and Share Exchange Agreement”), by and among Dr Ashleys Limited, a Cayman Islands exempted company limited by shares (“PubCo”), Impact, Dr Ashleys Nevada Sub, Inc., a Nevada corporation and wholly owned…
Entry Into a Material Definitive Agreement. Debt Conversion Agreement On July 21, 2025, Impact BioMedical Inc. (the “Company” or “Borrower”) entered into a Debt Conversion Agreement with DSS, Inc. (“DSS” or “Lender”), pursuant to that certain loan made on March 31, 2023, by the Lender in the form of a revolving promissory note in the original amount of $12,000,000 (the “Original Note”), which was amended on January 18, 2024 to (i) extend the maturity date of the Loan to September 30, 2023, (i…
Entry Into a Material Definitive Agreement. On June 21, 2025, Impact BioMedical Inc. (“Impact”), Dr Ashleys Limited, a Cayman Islands exempted company limited by shares (“PubCo”), Dr Ashleys Nevada Sub, Inc., a Nevada corporation and wholly-owned subsidiary of PubCo (“Merger Sub”), Dr Ashleys Bio Labs Limited, a Cayman Islands exempted company limited by shares (“Dr Ashleys Cayman”), and Kanans Visvanats (a.k.a. Kannan Vishwanatth), a Latvian national, solely in his capacity as the sole share…
Entry Into a Material Definitive Agreement. Debt Conversion Agreement As previously reported on the Company’s current report on Form 8-K, filed March 28, 2025 (the “Initial 8-K”), Impact BioMedical Inc. (the “Company”) entered into a Debt Conversion Agreement (the “Debt Conversion Agreement”), dated March 24, 2025, with DSS, Inc. (“DSS”), pursuant to that certain Amended and Restated Promissory Note, dated September 16, 2024 (the “Promissory Note”). The original principal amount of the Promis…
Entry Into a Material Definitive Agreement. Debt Conversion Agreement As previously reported, Impact BioMedical Inc. (the “Company”) entered into a Debt Conversion Agreement, dated March 24, 2025, with DSS, Inc., pursuant to that certain Amended and Restated Promissory Note, dated September 16, 2024 (the “Promissory Note”). The original principal amount of the Promissory Note was $12,000,000, and as of March 24, 2025, the Promissory Note had a principal balance of $13,176,477.03. In connectio…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 11, 2025, the Board of Directors of the Company appointed Mr. Chan Heng Fai Ambrose to serve as a Director of the Company, effective as of the same date. Mr. Chan Heng Fai Ambrose has over forty-five years of experience in the financial and equity investment industry. Mr. Chan is an expert in banking and finance. Mr. Chan has restructured…
Importance-ranked changes since the prior daily snapshot.
Confidence changed from 'low' to 'medium'.
Signal changed from 'None' to 'cautious'.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.